(News Bulletin 247) – Jefferies maintains its Buy recommendation on Biogen stock and its price target at $240.
‘The FDA briefing materials for Friday’s AdCom of Leqembi are relatively positive,’ begins the analyst who anticipates an upvote regarding his clinical benefit.
‘We expect straight-forward approval and no major labeling issues,’ the broker says.
The launch will take time in the second half of the year, but Jefferies expects it to ramp up in 2024,’ as medical centers build infusion capacity and the like. ‘.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
